Similar articles

• [Valganciclovir maintenance therapy in AIDS: treatment failure due to the development of cytomegalovirus resistance to ganciclovir].

  Couzigou C, Mazeron MC, Escaut L, Merad M, Vittecoq D. Couzigou C, et al. Med Mal Infect. 2005 Feb;35(2):98-100. doi: 10.1016/j.medmal.2004.11.005. Med Mal Infect. 2005. PMID: 15780901 Review. French. No abstract available.
• Cytomegalovirus ulcer. Successful treatment with valganciclovir.

  Lambert EM, Strasswimmer J, Lazova R, Antaya RJ. Lambert EM, et al. Arch Dermatol. 2004 Oct;140(10):1199-201. doi: 10.1001/archderm.140.10.1199. Arch Dermatol. 2004. PMID: 15492181 No abstract available.
• Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.

  Razonable RR, Paya CV. Razonable RR, et al. Expert Rev Anti Infect Ther. 2004 Feb;2(1):27-41. doi: 10.1586/14787210.2.1.27. Expert Rev Anti Infect Ther. 2004. PMID: 15482169 Review.
• A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

  Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ; Valganciclovir Study Group. Martin DF, et al. N Engl J Med. 2002 Apr 11;346(15):1119-26. doi: 10.1056/NEJMoa011759. N Engl J Med. 2002. PMID: 11948271 Clinical Trial.
• Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.

  Freeman RB. Freeman RB. Expert Opin Pharmacother. 2004 Sep;5(9):2007-16. doi: 10.1517/14656566.5.9.2007. Expert Opin Pharmacother. 2004. PMID: 15330737 Review.